Application of hot melt extrusion for improving bioavailability of artemisinin a thermolabile drug
View/ Open
Paradkar_et_al_Drug_Development_&_Industrial_Pharmacy.pdf (625.9Kb)
Download
Publication date
2017-11Rights
© 2017 Informa UK Limited, trading as Taylor & Francis Group. This is an Author's Original Manuscript of an article published by Taylor & Francis in Drug Development and Industrial Pharmacy on 16-11-2017 available online at http://www.tandfonline.com/10.1080/03639045.2017.1386200Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
2017-09-08
Metadata
Show full item recordAbstract
Hot melt extrusion has been used to produce a solid dispersion of the thermolabile drug artemisinin. Formulation and process conditions were optimised prior to evaluation of dissolution and biopharmaceutical performance. Soluplus®, a low Tg amphiphilic polymer especially designed for solid dispersions enabled melt extrusion at 110ºC although some drug-polymer incompatibility was observed. Addition of 5% citric acid as a pH modifier was found to suppress the degradation. The area under plasma concentration time curve (AUC0-24hr) and peak plasma concentration (Cmax) were four times higher for the modified solid dispersion compared to that of pure artemisinin.Version
Accepted manuscriptCitation
Kulkarni C, Kelly AL, Gough T et al (2017) Application of hot melt extrusion for improving bioavailability of artemisinin a thermolabile drug. Drug Development and Industrial Pharmacy. 44(2): 206-214.Link to Version of Record
https://doi.org/10.1080/03639045.2017.1386200Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1080/03639045.2017.1386200